Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -7.9x - -8.7x | -8.3x |
| Selected Fwd EBIT Multiple | 0.1x - 0.1x | 0.1x |
| Fair Value | ₩4,232 - ₩4,487 | ₩4,359 |
| Upside | 37.2% - 45.4% | 41.3% |
| Benchmarks | Ticker | Full Ticker |
| HLB Pep Co., Ltd. | A196300 | KOSDAQ:A196300 |
| SCM Lifescience Co., Ltd. | A298060 | KOSDAQ:A298060 |
| GeneOne Life Science, Inc. | A011000 | KOSE:A011000 |
| Genome & Company | A314130 | KOSDAQ:A314130 |
| GENINUS Inc. | A389030 | KOSDAQ:A389030 |
| Helixmith Co., Ltd | A084990 | KOSDAQ:A084990 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A196300 | A298060 | A011000 | A314130 | A389030 | A084990 | ||
| KOSDAQ:A196300 | KOSDAQ:A298060 | KOSE:A011000 | KOSDAQ:A314130 | KOSDAQ:A389030 | KOSDAQ:A084990 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | 16.8% | 25.8% | 11.4% | 58.5% | -12.5% | 47.8% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -54.8% | -2881.8% | -85.2% | -3344.6% | -159.2% | -1245.9% | |
| Prior Fiscal Year | -119.7% | -1868.3% | -120.3% | -385.4% | -144.7% | -838.9% | |
| Latest Fiscal Year | -87.3% | -1371.0% | -120.5% | -87.2% | -189.9% | -361.0% | |
| Latest Twelve Months | -120.6% | -816.1% | -110.3% | -72.3% | -161.0% | -296.5% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 13.49x | 25.60x | 6.14x | 3.37x | 9.77x | 10.98x | |
| EV / LTM EBITDA | -18.9x | -3.4x | -10.0x | -7.1x | -8.1x | -4.9x | |
| EV / LTM EBIT | -11.2x | -3.1x | -5.6x | -4.7x | -6.1x | -3.7x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -11.2x | -5.6x | -3.1x | ||||
| Historical EV / LTM EBIT | -20.5x | -6.7x | -1.7x | ||||
| Selected EV / LTM EBIT | -7.9x | -8.3x | -8.7x | ||||
| (x) LTM EBIT | (15,082) | (15,082) | (15,082) | ||||
| (=) Implied Enterprise Value | 118,578 | 124,819 | 131,060 | ||||
| (-) Non-shareholder Claims * | 83,424 | 83,424 | 83,424 | ||||
| (=) Equity Value | 202,002 | 208,243 | 214,484 | ||||
| (/) Shares Outstanding | 46.0 | 46.0 | 46.0 | ||||
| Implied Value Range | 4,386.88 | 4,522.42 | 4,657.95 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 4,386.88 | 4,522.42 | 4,657.95 | 3,085.00 | |||
| Upside / (Downside) | 42.2% | 46.6% | 51.0% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A196300 | A298060 | A011000 | A314130 | A389030 | A084990 | |
| Enterprise Value | 64,945 | 33,066 | 233,744 | 100,331 | 70,884 | 58,630 | |
| (+) Cash & Short Term Investments | 17,504 | 2,714 | 3,944 | 78,024 | 8,895 | 81,429 | |
| (+) Investments & Other | 1 | 0 | 17 | 0 | 0 | 1,803 | |
| (-) Debt | (6,244) | (6,857) | (30,171) | (32,535) | (8,239) | (243) | |
| (-) Other Liabilities | 0 | 0 | 0 | (50,604) | 0 | 436 | |
| (-) Preferred Stock | 0 | 0 | 0 | (872) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 76,206 | 28,924 | 207,534 | 94,345 | 71,540 | 142,055 | |
| (/) Shares Outstanding | 9.3 | 32.8 | 84.7 | 31.1 | 33.4 | 46.0 | |
| Implied Stock Price | 8,200.00 | 883.00 | 2,450.00 | 3,035.00 | 2,145.00 | 3,085.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 8,200.00 | 883.00 | 2,450.00 | 3,035.00 | 2,145.00 | 3,085.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |